Publications by authors named "V Bellani"
Article Synopsis
- - The introduction of small molecule tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has significantly improved patient life expectancy, making it comparable to the general population, despite potential mild to severe side effects from long-term use.
- - Emerging goals in CML treatment include the potential for treatment-free remission (TFR), with specific eligibility criteria, where 25%-30% of patients might achieve prolonged TFR.
- - This review focuses on guidelines for safely stopping TKIs, shares clinical insights from trials and real-world data, and highlights ongoing research into biological markers that could help predict TFR success.
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.
View Article and Find Full Text PDFControlling the surface diffusion of particles on 2D devices creates opportunities for advancing microscopic processes such as nanoassembly, thin-film growth, and catalysis. Here, we demonstrate the ability to control the diffusion of FTCNQ molecules at the surface of clean graphene field-effect transistors (FETs) via electrostatic gating. Tuning the back-gate voltage () of a graphene FET switches molecular adsorbates between negative and neutral charge states, leading to dramatic changes in their diffusion properties.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed clinical and genetic data from 28 patients with idiopathic hypereosinophilia (HE) over a 10-year period, focusing on bone marrow morphology and mutational profiles using next-generation sequencing (NGS).
- Out of 22 patients assessed for bone marrow (BM) morphology, 6 were normal, while 16 showed increased eosinophils and mild fibrosis; 4 patients had identifiable genetic mutations, including JAK2V617F and TET2.
- The findings suggest that somatic mutations were rare (only 14.3% of patients) and caution is advised in interpreting these mutations without considering other clinical evidence, especially in older patients.
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%.
View Article and Find Full Text PDF